Equities

Xbrane Biopharma AB

Xbrane Biopharma AB

Actions
  • Price (EUR)0.0093
  • Today's Change-0.007 / -43.29%
  • Shares traded4.00k
  • 1 Year change-96.81%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 09:52 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of SEK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments65194295
Total Receivables, Net344750
Total Inventory10750--
Prepaid expenses252152147
Other current assets, total3.327069
Total current assets462514561
Property, plant & equipment, net887174
Goodwill, net000
Intangibles, net10010250
Long term investments------
Note receivable - long term3.953.953.95
Other long term assets--0.000
Total assets654691688
LIABILITIES
Accounts payable312341
Accrued expenses1356666
Notes payable/short-term debt000
Current portion long-term debt/capital leases769.167.91
Other current liabilities, total85138105
Total current liabilities327237220
Total long term debt1562936
Total debt2313844
Deferred income tax------
Minority interest00--
Other liabilities, total0.0100.54
Total liabilities482266257
SHAREHOLDERS EQUITY
Common stock6.686.175.61
Additional paid-in capital1,4291,2941,134
Retained earnings (accumulated deficit)(1264)(876)(708)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total----0.00
Total equity171425432
Total liabilities & shareholders' equity654691688
Total common shares outstanding263243221
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.